KALA BIO, INC. Capital Expenditures
KALA BIO, INC. (KALA) reported Capital Expenditures of $1.46 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2020-11-05
- KALA BIO, INC. payments to acquire property, plant, and equipment for the quarter ending 2020-09-30 was $544.00K, a 166.67% increase year-over-year.
- KALA BIO, INC. payments to acquire property, plant, and equipment for the quarter ending 2020-06-30 was $623.00K, a 24.85% increase year-over-year.
- KALA BIO, INC. payments to acquire property, plant, and equipment for the quarter ending 2020-03-31 was $292.00K, a 34.23% decline year-over-year.
- KALA BIO, INC. payments to acquire property, plant, and equipment for the quarter ending 2019-12-31 was $188.00K, a 79.34% decline year-over-year.
- KALA BIO, INC. payments to acquire property, plant, and equipment for fiscal 2019 was $1.33M, a 15.40% decline from fiscal 2018.
- KALA BIO, INC. payments to acquire property, plant, and equipment for fiscal 2018 was $1.58M, a 228.75% increase from fiscal 2017.
- KALA BIO, INC. payments to acquire property, plant, and equipment for fiscal 2017 was $480.00K, a 213.73% increase from fiscal 2016.
- KALA BIO, INC. payments to acquire property, plant, and equipment for fiscal 2016 was $153.00K, a 39.29% decline from fiscal 2015.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 3 month as first filed | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 6 month as first filed | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 9 month as first filed | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|---|---|---|
| 2020-09-30 | $544.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.17M derived: sum of 2 quarters · filed 2020-11-05 | $1.46M 10-Q · filed 2020-11-05 | $1.65M derived: sum of 4 quarters · filed 2020-11-05 | |||
| 2020-06-30 | $623.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $915.00K 10-Q · filed 2020-08-06 | $1.10M derived: sum of 3 quarters · filed 2020-08-06 | $1.31M derived: sum of 4 quarters · filed 2020-11-05 | |||
| 2020-03-31 | $292.00K 10-Q · filed 2020-05-07 | $480.00K derived: sum of 2 quarters · filed 2020-05-07 | $684.00K derived: sum of 3 quarters · filed 2020-11-05 | $1.18M derived: sum of 4 quarters · filed 2020-11-05 | |||
| 2019-12-31 | $188.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | $392.00K derived: sum of 2 quarters · filed 2020-11-05 | $891.00K derived: sum of 3 quarters · filed 2020-11-05 | $1.33M 10-K · filed 2020-02-12 | |||
| 2019-09-30 | $204.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $703.00K derived: sum of 2 quarters · filed 2020-11-05 | $1.15M 10-Q · filed 2020-11-05 | $2.06M derived: sum of 4 quarters · filed 2020-11-05 | |||
| 2019-06-30 | $499.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $943.00K 10-Q · filed 2020-08-06 | $1.85M derived: sum of 3 quarters · filed 2020-08-06 | $1.98M derived: sum of 4 quarters · filed 2020-08-06 | |||
| 2019-03-31 | $444.00K 10-Q · filed 2020-05-07 | $1.35M derived: sum of 2 quarters · filed 2020-05-07 | $1.48M derived: sum of 3 quarters · filed 2020-05-07 | $1.65M derived: sum of 4 quarters · filed 2020-05-07 | |||
| 2018-12-31 | $910.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | $1.04M derived: sum of 2 quarters · filed 2020-02-12 | $1.21M derived: sum of 3 quarters · filed 2020-02-12 | $1.58M 10-K · filed 2020-02-12 | |||
| 2018-09-30 | $127.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $295.00K derived: sum of 2 quarters · filed 2019-11-07 | $668.00K 10-Q · filed 2019-11-07 | $950.00K derived: sum of 4 quarters · filed 2019-11-07 | |||
| 2018-06-30 | $168.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $541.00K 10-Q · filed 2019-08-06 | $545.00K 10-Q · filed 2018-08-09 | $823.00K derived: sum of 3 quarters · filed 2019-08-06 | $912.00K derived: sum of 4 quarters · filed 2019-08-06 | ||
| 2018-03-31 | $373.00K 10-Q · filed 2019-05-09 | $377.00K 10-Q · filed 2018-05-10 | $655.00K derived: sum of 2 quarters · filed 2019-05-09 | $744.00K derived: sum of 3 quarters · filed 2019-05-09 | $781.00K derived: sum of 4 quarters · filed 2019-05-09 | ||
| 2017-12-31 | $282.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $371.00K derived: sum of 2 quarters · filed 2019-03-12 | $408.00K derived: sum of 3 quarters · filed 2019-03-12 | $480.00K 10-K · filed 2019-03-12 | |||
| 2017-09-30 | $89.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $126.00K derived: sum of 2 quarters · filed 2018-11-08 | $198.00K 10-Q · filed 2018-11-08 | $197.00K 10-Q · filed 2017-11-07 | $256.00K derived: sum of 4 quarters · filed 2018-11-08 | ||
| 2017-06-30 | $37.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $109.00K 10-Q · filed 2018-08-09 | $167.00K derived: sum of 3 quarters · filed 2018-08-09 | $216.00K derived: sum of 4 quarters · filed 2018-08-09 | |||
| 2017-03-31 | $72.00K 10-Q · filed 2018-05-10 | $130.00K derived: sum of 2 quarters · filed 2018-05-10 | $179.00K derived: sum of 3 quarters · filed 2018-05-10 | ||||
| 2016-12-31 | $58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $107.00K derived: sum of 2 quarters · filed 2018-04-02 | $153.00K 10-K · filed 2018-04-02 | ||||
| 2016-09-30 | $49.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $95.00K 10-Q · filed 2017-11-07 | |||||
| 2016-06-30 | $46.00K 10-Q · filed 2017-08-31 | ||||||
| 2015-12-31 | $252.00K 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |